<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82894">
  <stage>Registered</stage>
  <submitdate>11/06/2008</submitdate>
  <approvaldate>16/06/2008</approvaldate>
  <actrnumber>ACTRN12608000299303</actrnumber>
  <trial_identification>
    <studytitle>The effects of vitamin D supplementation on bone density in vitamin D insufficient teenagers: randomised controlled trial</studytitle>
    <scientifictitle>The effects of vitamin D supplementation on bone density in vitamin D insufficient teenagers: randomised placebo-controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bone development</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>150 000 international units (IU) (3 x 50 000 IU vitamin D3 tablets with 3 x identical inert placebo tablets) or 300 000 IU (6 x 50 000 IU vitamin D3 tablets) of vitamin D3 given orally every 6 months for 2 years</interventions>
    <comparator>Oral 6 monthly dose of 6 x inert identical placebo tablets for 2 years.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>bone density (femoral neck bone mineral density, lumbar spine bone mineral density and total body bone mineral content) measured by Hologic Delphi bone densitometer</outcome>
      <timepoint>baseline, 12 months and 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>quantitative heel ultrasound measured at the heel by Sahara Clinical Bone Sonometer</outcome>
      <timepoint>baseline, then 6 monthly until 24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.healthy adolescents aged 15-17 years
2. mild to moderate vitamin D deficiency (serum 25-hydroxy vitamin D 12.5-50 nmol/L measured in July to October).
3.  no known severe renal impairment, malabsorption, pregnancy, or lactation.
4.  no clinical signs of rickets.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. severe vitamin D deficiency (serum 25-hydroxy vitamin D less than 12.5 nmol/l)
2. vitamin D replete i.e. serum 25-hydroxy vitamin D greater than or equal to 50 nmol/L .
3.  known severe renal impairment, malabsorption, pregnancy, or lactation.
4.  clinical signs of rickets.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Adolescents will be recruited by invitation through their schools.  Allocation concealment will be ensured by the use of identical inert placebo, and a security protected central automated allocation procedure.  Allocation will be of individual participants.</concealment>
    <sequence>Allocation will by computer generated random numbers.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>21/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>670</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Menzies Research Institute</primarysponsorname>
    <primarysponsoraddress>2/199 Macquarie St
Hobart Tasmania</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Hobart Hospital Research Foundation</fundingname>
      <fundingaddress>Ground Floor "C Block" GPO Box 1061 
48 Liverpool Street Hobart Tasmania 7001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Osteoporosis fractures are common, costly and cause significant death and disability. They may be reduced
by improving the amount of bone laid down in childhood. Childhood vitamin D deficiency is common and is
harmful for bone development. The use of vitamin D supplements in children to improve bone health needs
further investigation. This study aims to determine what effect vitamin supplementation has on bone
development in adolescents who have mild to moderate vitamin D deficiency. This will be tested through a
placebo controlled randomised controlled trial of vitamin D supplementation in a sample of mild to
moderately vitamin D deficient adolescents aged 15 to 17 years.</summary>
    <trialwebsite>none</trialwebsite>
    <publication>None as yet</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmania Health and Medical Human research ethics Committee</ethicname>
      <ethicaddress>University of Tasmania
Private Bag 1
Hobart TAS 7001</ethicaddress>
      <ethicapprovaldate>2/03/2008</ethicapprovaldate>
      <hrec>H9854</hrec>
      <ethicsubmitdate>14/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tania Winzenberg</name>
      <address>Private Bag 23
Hobart TAS 7001</address>
      <phone>613 62267700</phone>
      <fax>613 62267704</fax>
      <email>tania.winzenberg@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tania Winzenberg</name>
      <address>Private Bag 23
Hobart TAS 7001</address>
      <phone>613 62267700</phone>
      <fax>613 62267704</fax>
      <email>tania.winzenberg@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tania Winzenberg</name>
      <address>Private Bag 23
Hobart TAS 7001</address>
      <phone>613 62267700</phone>
      <fax>613 62267704</fax>
      <email>tania.winzenberg@utas.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>